Electroporation delivery of DNA vaccines: Prospects for success

Current Opinion in Immunology

Volumn 23, Issue 3, 2011, Pages 421-429

  Sardesai, Niranjan Y ^a   Weiner, David B ^b  

^a Inovio Pharmaceuticals   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; HEPATITIS C VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; SMALLPOX VACCINE; TETANUS TOXOID; VIRUS VECTOR;

APPLICATION SITE PAIN; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; ELECTROPORATION; EXPERIMENTAL MODEL; GOOD MANUFACTURING PRACTICE; HEPATITIS C; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; INFECTION PREVENTION; INFLUENZA; INTERMETHOD COMPARISON; NONHUMAN; PIEZOELECTRICITY; REVIEW; SMALLPOX; TETANUS; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CLINICAL TRIALS AS TOPIC; ELECTROPORATION; GENE EXPRESSION REGULATION; HUMANS; IMMUNE TOLERANCE; VACCINES, DNA;

EID: 79957781340     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2011.03.008     Document Type: Review

References (75)

1. Tang D.C., DeVit M., Johnston S.A. Genetic immunization is a simple method for eliciting an immune response. Nature 1992, 356:152-154.
2. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., Gromkowski S.H., Deck R.R., DeWitt C.M., Friedman A., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993, 259:1745-1749.
3. Wang B., Ugen K.E., Srikantan V., Agadjanyan M.G., Dang K., Refaeli Y., Sato A.I., Boyer J., Williams W.V., Weiner D.B. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993, 90:4156-4160.
4. Fattori E., La Monica N., Ciliberto G., Toniatti C. Electro-gene-transfer: a new approach for muscle gene delivery. Somat Cell Mol Genet 2002, 27:75-83.
5. Ulmer J.B., Wahren B., Liu M.A. Gene-based vaccines: recent technical and clinical advances. Trends Mol Med 2006, 12:216-222.
6. Hooper J.W., Golden J.W., Ferro A.M., King A.D. Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. Vaccine 2007, 25:1814-1823.
7. Hirao L.A., Draghia-Akli R., Prigge J.T., Yang M., Satishchandran A., Wu L., Hammarlund E., Khan A.S., Babas T., Rhodes L., et al. Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge. J Infect Dis 2010, 203:95-102.
8. Choo A.Y., Broderick K.E., Kim J.J., Sardesai N.Y. DNA-based influenza vaccines: evaluating their potential to provide universal protection. IDrugs 2010, 13:707-712.
9. Laddy D.J., Yan J., Corbitt N., Kobasa D., Kobinger G.P., Weiner D.B. Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine 2007, 25:2984-2989.
10. Yan J., Yoon H., Kumar S., Ramanathan M.P., Corbitt N., Kutzler M., Dai A., Boyer J.D., Weiner D.B. Enhanced cellular immune responses elicited by an engineered HIV-1 subtype B consensus-based envelope DNA vaccine. Mol Ther 2007, 15:411-421.
11. Santra S., Liao H.X., Zhang R., Muldoon M., Watson S., Fischer W., Theiler J., Szinger J., Balachandran H., Buzby A., et al. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med 2010, 16:324-328.
12. Lang K.A., Yan J., Draghia-Akli R., Khan A., Weiner D.B. Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine. Vaccine 2008, 26:6225-6231.
13. Ramanathan M.P., Kuo Y.C., Selling B.H., Li Q., Sardesai N.Y., Kim J.J., Weiner D.B. Development of a novel DNA SynCon tetravalent dengue vaccine that elicits immune responses against four serotypes. Vaccine 2009, 27:6444-6453.
14. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., et al. A toll-like receptor recognizes bacterial DNA. Nature 2000, 408:740-745.
15. Spies B., Hochrein H., Vabulas M., Huster K., Busch D.H., Schmitz F., Heit A., Wagner H. Vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice. J Immunol 2003, 171:5908-5912.
16. Takaoka A., Wang Z., Choi M.K., Yanai H., Negishi H., Ban T., Lu Y., Miyagishi M., Kodama T., Honda K., et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 2007, 448:501-505.
17. Wang Z., Choi M.K., Ban T., Yanai H., Negishi H., Lu Y., Tamura T., Takaoka A., Nishikura K., Taniguchi T. Regulation of innate immune responses by DAI (DLM-1/ZBP1) and other DNA-sensing molecules. Proc Natl Acad Sci USA 2008, 105:5477-5482.
18. Burckstummer T., Baumann C., Bluml S., Dixit E., Durnberger G., Jahn H., Planyavsky M., Bilban M., Colinge J., Bennett K.L., et al. An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat Immunol 2009, 10:266-272.
19. Fernandes-Alnemri T., Yu J.W., Datta P., Wu J., Alnemri E.S. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 2009, 458:509-513.
20. Yanai H., Ban T., Wang Z., Choi M.K., Kawamura T., Negishi H., Nakasato M., Lu Y., Hangai S., Koshiba R., et al. HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature 2009, 462:99-103.
21. Rice J., Ottensmeier C.H., Stevenson F.K. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 2008, 8:108-120.
22. Hung C.F., Hsu K.F., Cheng W.F., Chai C.Y., He L., Ling M., Wu T.C. Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand. Cancer Res 2001, 61:1080-1088.
23. Zanetti M. T for two: when helpers need help. Autoimmun Rev 2005, 4:571-578.
24. Kim J.J., Ayyavoo V., Bagarazzi M.L., Chattergoon M.A., Dang K., Wang B., Boyer J.D., Weiner D.B. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J Immunol 1997, 158:816-826.
25. Schadeck E.B., Sidhu M., Egan M.A., Chong S.Y., Piacente P., Masood A., Garcia-Hand D., Cappello S., Roopchand V., Megati S., et al. A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques. Vaccine 2006, 24:4677-4687.
26. Arcuri M., Cappelletti M., Zampaglione I., Aurisicchio L., Nicosia A., Ciliberto G., Fattori E. Synergistic effect of gene-electro transfer and adjuvant cytokines in increasing the potency of hepatitis C virus genetic vaccination. J Gene Med 2008, 10:1048-1054.
27. Morrow M.P., Yan J., Pankhong P., Ferraro B., Lewis M.G., Khan A.S., Sardesai N.Y., Weiner D.B. Unique Th1/Th2 phenotypes induced during priming and memory phases by use of interleukin-12 (IL-12) or IL-28B vaccine adjuvants in rhesus macaques. Clin Vaccine Immunol 2010, 17:1493-1499.
28. Stevenson F.K., Ottensmeier C.H., Rice J. DNA vaccines against cancer come of age. Curr Opin Immunol 2010, 22:264-270.
29. Low L., Mander A., McCann K., Dearnaley D., Tjelle T., Mathiesen I., Stevenson F., Ottensmeier C.H. DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum Gene Ther 2009, 20:1269-1278.
30. Draghia-Akli R., Khan A. Gene and Cell Therapy: Therapeutic Mechanisms and Strategies 2009, Nancy Templeton Smith CRC Press, 363-371. edn 3.
31. Cukjati D., Batiuskaite D., Andre F., Miklavcic D., Mir L.M. Real time electroporation control for accurate and safe in vivo non-viral gene therapy. Bioelectrochemistry 2007, 70:501-507.
32. Trollet C., Bloquel C., Scherman D., Bigey P. Electrotransfer into skeletal muscle for protein expression. Curr Gene Ther 2006, 6:561-578.
33. Becker S.M., Kuznetsov A.V. Local temperature rises influence in vivo electroporation pore development: a numerical stratum corneum lipid phase transition model. J Biomech Eng 2007, 129:712-721.
34. Luckay A., Sidhu M.K., Kjeken R., Megati S., Chong S.Y., Roopchand V., Garcia-Hand D., Abdullah R., Braun R., Montefiori D.C., et al. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol 2007, 81:5257-5269.
35. Liu J., Ewald B.A., Lynch D.M., Denholtz M., Abbink P., Lemckert A.A., Carville A., Mansfield K.G., Havenga M.J., Goudsmit J., et al. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J Virol 2008, 82:4844-4852.
36. Hirao L.A., Wu L., Khan A.S., Hokey D.A., Yan J., Dai A., Betts M.R., Draghia-Akli R., Weiner D.B. Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine 2008, 26:3112-3120.
37. Rosati M., Valentin A., Jalah R., Patel V., von Gegerfelt A., Bergamaschi C., Alicea C., Weiss D., Treece J., Pal R., et al. Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation. Vaccine 2008, 26:5223-5229.
38. Simon A.J., Casimiro D.R., Finnefrock A.C., Davies M.E., Tang A., Chen M., Chastain M., Kath G.S., Chen L., Shiver J.W. Enhanced in vivo transgene expression and immunogenicity from plasmid vectors following electrostimulation in rodents and primates. Vaccine 2008, 26:5202-5209.
39. Hirao L.A., Wu L., Satishchandran A., Khan A.S., Draghia-Akli R., Finnefrock A.C., Bett A.J., Betts M.R., Casimiro D.R., Sardesai N.Y., et al. Comparative analysis of immune responses induced by vaccination with SIV antigens by recombinant Ad5 vector or plasmid DNA in rhesus macaques. Mol Ther 2010, 18:1568-1576.
40. Dobano C., Widera G., Rabussay D., Doolan D.L. Enhancement of antibody and cellular immune responses to malaria DNA vaccines by in vivo electroporation. Vaccine 2007, 25:6635-6645.
41. LeBlanc R., Vasquez Y., Hannaman D., Kumar N. Markedly enhanced immunogenicity of a Pfs25 DNA-based malaria transmission-blocking vaccine by in vivo electroporation. Vaccine 2008, 26:185-192.
42. Ahlen G., Soderholm J., Tjelle T., Kjeken R., Frelin L., Hoglund U., Blomberg P., Fons M., Mathiesen I., Sallberg M. In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells. J Immunol 2007, 179:4741-4753.
43. Luxembourg A., Hannaman D., Wills K., Bernard R., Tennant B.C., Menne S., Cote P.J. Immunogenicity in mice and rabbits of DNA vaccines expressing woodchuck hepatitis virus antigens. Vaccine 2008, 26:4025-4033.
44. van Drunen Littel-van den Hurk S., Luxembourg A., Ellefsen B., Wilson D., Ubach A., Hannaman D., van den Hurk J.V. Electroporation-based DNA transfer enhances gene expression and immune responses to DNA vaccines in cattle. Vaccine 2008, 26:5503-5509.
45. Kim C.Y., Kang E.S., Kim S.B., Kim H.E., Choi J.H., Lee D.S., Im S.J., Yang S.H., Sung Y.C., Kim B.M., et al. Increased in vivo immunological potency of HB-110, a novel therapeutic HBV DNA vaccine, by electroporation. Exp Mol Med 2008, 40:669-676.
46. Nystrom J., Chen A., Frelin L., Ahlen G., Koh S., Brass A., Peterson D.L., Fons M., Milich D.R., Hultgren C., et al. Improving on the ability of endogenous hepatitis B core antigen to prime cytotoxic T lymphocytes. J Infect Dis 2010, 201:1867-1879.
47. Trollet C., Pereira Y., Burgain A., Litzler E., Mezrahi M., Seguin J., Manich M., Popoff M.R., Scherman D., Bigey P. Generation of high-titer neutralizing antibodies against botulinum toxins A, B, and E by DNA electrotransfer. Infect Immun 2009, 77:2221-2229.
48. Best S.R., Peng S., Juang C.M., Hung C.F., Hannaman D., Saunders J.R., Wu T.C., Pai S.I. Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine 2009, 27:5450-5459.
49. Seo S.H., Jin H.T., Park S.H., Youn J.I., Sung Y.C. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation. Vaccine 2009, 27:5906-5912.
50. Livingston B.D., Little S.F., Luxembourg A., Ellefsen B., Hannaman D. Comparative performance of a licensed anthrax vaccine versus electroporation based delivery of a PA encoding DNA vaccine in rhesus macaques. Vaccine 2010, 28:1056-1061.
51. Laddy D.J., Yan J., Khan A.S., Andersen H., Cohn A., Greenhouse J., Lewis M., Manischewitz J., King L.R., Golding H., et al. Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J Virol 2009, 83:4624-4630.
52. Laddy D.J., Yan J., Kutzler M., Kobasa D., Kobinger G.P., Khan A.S., Greenhouse J., Sardesai N.Y., Draghia-Akli R., Weiner D.B. Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS ONE 2008, 3:e2517.
53. Hirao L.A., Wu L., Khan A.S., Satishchandran A., Draghia-Akli R., Weiner D.B. Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine 2008, 26:440-448.
54. Broderick K.E., Shen X., Soderholm J., Lin F., McCoy J., Khan A.S., Yan J., Morrow M.P., Patel A., Kobinger G.P., et al. Prototype development and preclinical immunogenicity analysis of a novel minimally invasive electroporation device. Gene Ther 2011, 18:258-265.
55. Dolter K.E., Evans C.F., Ellefsen B., Song J., Boente-Carrera M., Vittorino R., Rosenberg T.J., Hannaman D., Vasan S. Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation. Vaccine 2010, 29:795-803.
56. Tobin D.J. Biochemistry of human skin - our brain on the outside. Chem Soc Rev 2006, 35:52-67.
57. Martinon F., Kaldma K., Sikut R., Culina S., Romain G., Tuomela M., Adojaan M., Mannik A., Toots U., Kivisild T., et al. Persistent immune responses induced by a human immunodeficiency virus DNA vaccine delivered in association with electroporation in the skin of nonhuman primates. Hum Gene Ther 2009, 20:1291-1307.
58. Broderick K., Kardos T., McCoy J.R., Fons M.P., Kemmerrer S., Sardesai N.Y. Piezoelectric permeabilization of mammalian dermal tissue for in vivo DNA delivery leads to enhanced protein expression and increased immunogenicity. Hum Vaccin. 2011, 7. Jan 1 [Epub ahead of print].
59. Lin F., Shen X., McCoy J.B., Mendoza J.M., Yan J., Kemmerrer S., Khan A.S., Weiner D.B., Broderick K.E., Sardesai N.Y. A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle. Vaccine 2011, Jan 1 [Epub ahead of print].
60. Roos A.K., Eriksson F., Timmons J.A., Gerhardt J., Nyman U., Gudmundsdotter L., Brave A., Wahren B., Pisa P. Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment. PLoS ONE 2009, 4:e7226.
61. Brave A., Johansson U., Hallengard D., Heidari S., Gullberg H., Wahren B., Hinkula J., Spetz A.L. Induction of HIV-1-specific cellular and humoral immune responses following immunization with HIV-DNA adjuvanted with activated apoptotic lymphocytes. Vaccine 2010, 28:2080-2087.
62. Ledwith B.J., Manam S., Troilo P.J., Barnum A.B., Pauley C.J., Griffiths T.G., Harper L.B., Beare C.M., Bagdon W.J., Nichols W.W. Plasmid DNA vaccines: investigation of integration into host cellular DNA following intramuscular injection in mice. Intervirology 2000, 43:258-272.
63. Sallberg M., Frelin L., Diepolder H.M., Jung M.C., Mathiesen I., Fons M., Ahlen G., Chen M., Weiland O. Therapeutic DNA vaccination followed by standard-of-care therapy in patients with chronic hepatitis C: a rapid clearance of viremia. Mol Ther 2010, 18:S110.
64. Wallace M., Evans B., Woods S., Mogg R., Zhang L., Finnefrock A.C., Rabussay D., Fons M., Mallee J., Mehrotra D., et al. Tolerability of two sequential electroporation treatments using MedPulser DNA delivery system (DDS) in healthy adults. Mol Ther 2009, 17:922-928.
65. Yan J., Pankhong P., Shen X., Giffear M., Lee J., Harris D., Diaz D., Khan A., Bagarazzi M., Boyer J., et al. Phase I safety and immunogenicity of HPV 16 and 18 DNA vaccines delivered via electroporation. Mol Ther 2010, 18:S184.
66. Lee J., Khan A., Giffear M., Diep-Lam P., Zifchak L., Maslow J., Tebas P., Sardesai N.Y. Tolerability of EP by Cellectra device following intradermal administration of saline in healthy volunteers. ASGCT Conference poster 2010.
67. Ottensmeier C., Low L., Mander A., Tjelle T., Campos-perez J., Williams T., Heath C., Dearnaley D., Mathiesen I., Stevenson F. DNA fusion gene vaccination, delivered with or without in vivo electroporation: a potent and safe strategy for inducing antitumor immune response in prostate cancer. AACR Meeting Abstracts 2008, 2843.
68. Vasan S., Hurley A., Schlesinger S.J., Hannaman D., Gardiner D.F., Dugin D.P., Boente-Carrera M.M., Vittorino R.M., Caskey M., Andersen J., et al. In vivo electroporation enhances the immunogenicity of ADVAX, a DNA-based HIV-1 vaccine candidate, in healthy volunteers. AIDS Vaccine Conference Abstract 2009, 55.
69. Vasan S., Schlesinger S.J., Huang Y., Hurley A., Lombardo A., Chen Z., Than S., Adesanya P., Bunce C., Boaz M., et al. Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine. PLoS ONE 2010, 5:e8617.
70. Bagarazzi M., Yan J., Shen X., Giffear M., Lee J., Khan A., Harris D., Pankhong P., Shedlock D., Boyer J., et al. Immunotherapy of post-LEEP CIN2/3 with HPV 16 and 18 E6/E7 DNA vaccines/electroporation. 50th ICAAC Boston, poster G1-202 2010.
71. Trimble C.L., Peng S., Kos F., Gravitt P., Viscidi R., Sugar E., Pardoll D., Wu T.C. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res 2009, 15:361-367.
72. Kenter G.G., Welters M.J., Valentijn A.R., Lowik M.J., Berends-van der Meer D.M., Vloon A.P., Essahsah F., Fathers L.M., Offringa R., Drijfhout J.W., et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009, 361:1838-1847.
73. Listner K., Bentley L., Okonkowski J., Kistler C., Wnek R., Caparoni A., Junker B., Robinson D., Salmon P., Chartrain M. Development of a highly productive and scalable plasmid DNA production platform. Biotechnol Prog 2006, 22:1335-1345.
74. Victoria J.G., Wang C., Jones M.S., Jaing C., McLoughlin K., Gardner S., Delwart E.L. Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus. J Virol 2010, 84:6033-6040.
75. Onions D., Kolman J. Massively parallel sequencing, a new method for detecting adventitious agents. Biologicals 2010, 38:377-380.